You are here: Industry Insights > Pfizer

News List

Merck and Pfizer provide update on avelumab in platinum-resistant/refractory ovarian cancer worldpharmanews
November 20, 2018
Four out of five patients with ovarian cancer are diagnosed at advanced stages. The disease often has no symptoms early on, when it is much more treatable.
Pfizer CEO Ian Read set to step down from head position pharmafile
November 20, 2018
Ian Read is set to step down from his position as Chief Executive Officer (CEO) of American pharma firm Pfizer, having led the company for the past eight years.
Pfizer, plotting 41 price hikes for January, returns to 'business as normal' after price-raising pause fiercepharma
November 20, 2018
Pfizer, which became the center of a drug pricing controversy this summer featuring President Donald Trump, has decided it’s ready to raise prices in early 2019.
AstraZeneca begins succession planning for CEO Soriot: report firstwordpharma
November 19, 2018
AstraZeneca has started looking for candidates to succeed CEO Pascal Soriot amid pressure from shareholders, reported the Sunday Times without citing sources.
Array BioPharma collaborates with Pfizer biospectrumasia
November 19, 2018
Novel combinations of binimetinib (MEK), avelumab (PD-L1), and talazoparib (PARP inhibitor) to be studied across tumor types
Pfizer loses landmark second medical use patent case pharmatimes
November 19, 2018
The UK Supreme Court has ruled against Pfizer in a long-running legal battle over the validity of a second medical use patent protecting pregabalin.
Pfizer loses Lyrica patent case in UK Supreme Court pharmaceutical-technology
November 16, 2018
The UK Supreme Court has ruled against Pfizer in a long running legal case involving a second medical use patent for its Lyrica (pregabalin) drug.
Pfizer falls short in U.K. patent appeal for blockbuster Lyrica fiercepharma
November 15, 2018
Pfizer has come up short in a long-running patent battle in the U.K. over its blockbuster Lyrica, and the loss could come with a significant financial hit for the drugmaker.
Kymera Therapeutics Announces $65 Million Series B Financing to Advance Pipeline of Targeted Protein Degraders in Oncology and Immunology firstwordpharma
November 14, 2018
CAMBRIDGE, Mass., Nov. 13, 2018 /PRNewswire/ -- Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to create breakthrough
Nektar, Pfizer Announce Oncology Clinical Collaboration americanpharmaceuticalreview
November 10, 2018
Nektar Therapeutics has entered into an oncology clinical collaboration with Pfizer to evaluate several combination regimens in multiple cancer settings, including metastatic castration-resistant prostate cancer (mCRPC) and squamous cell carcinoma of the

Previous page 1 2 3 4 5 6 7 8 9 10 ... 83 84 Next page